Middle East Pharmaceutical Industries Company (TADAWUL:4016)

Market Cap	2.63B
Revenue (ttm)	387.18M
Net Income (ttm)	80.44M
Shares Out	20.00M
EPS (ttm)	4.02
PE Ratio	32.72
Forward PE	26.86
Dividend	1.50 (1.14%)
Ex-Dividend Date	n/a

Volume	11,363
Average Volume	44,347
Open	131.60
Previous Close	131.60
Day's Range	130.20 - 131.60
52-Week Range	107.00 - 161.20
Beta	n/a
RSI	48.76
Earnings Date	Mar 26, 2025

About TADAWUL:4016

Middle East Pharmaceutical Industries Company engages in the research, development, manufacture, and marketing of generic medicines and pharmaceutical preparations in the Kingdom of Saudi Arabia and internationally. The company operates through three segments: Private, Public, and Export. It offers medicines and preparations used to treat skin diseases, skin creams, and skin care products; respiratory, central nervous, digestive, and musculoskeletal system medicines; urinary and reproductive system drugs; disinfectants; and various therapeutic ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1998
• Employees: 543
• Stock Exchange: Saudi Stock Exchange
• Ticker Symbol: 4016

Financial Performance

In 2023, TADAWUL:4016's revenue was 338.44 million, an increase of 11.82% compared to the previous year's 302.66 million. Earnings were 65.83 million, an increase of 10.72%.